



Richard Lafayette

Professor of Medicine (Nephrology)

Medicine - Nephrology

CLINICAL OFFICE (PRIMARY)

- **Nephrology Clinic**

300 Pasteur Dr Ste A175

MC 5309

Stanford, CA 94305

Tel (650) 723-6961

Fax (650) 725-8418

ACADEMIC CONTACT INFORMATION

- **Alternate Contact**

Samantha Smith - Administrative Coordinator

Email smasmith@stanford.edu

Tel 650-497-8664

Bio

BIO

Dr. Richard Lafayette is Professor of Medicine (Nephrology) at the Stanford University Medical Center. Founder and director of the Stanford Glomerular Disease Center and its fellowship training program. This interest has led to many evaluations and some elucidation of the pathogenesis of IgA nephritis and leadership in numerous clinical trials. He has more than 30 years of clinical experience and has more than 150 publications including more than 100 peer reviewed papers. He remains passionate in efforts to discover safer and more effective treatments for patients.

CLINICAL FOCUS

- Nephrology (Kidney)
- Glomerular Disease
- Amyloidosis
- Kidney and Pancreas Transplantation
- Nephrology

ACADEMIC APPOINTMENTS

- Professor - University Medical Line, Medicine - Nephrology
- Member, Cardiovascular Institute

ADMINISTRATIVE APPOINTMENTS

- Associate Chair, Stanford University School of Medicine - Medicine, (2002-2007)
- Clinical Chief, Nephrology, Stanford University, (1999-2012)
- Director, Stanford Glomerular Disease Center, (2010- present)

HONORS AND AWARDS

- America's Top Doctors, Best Doctors (2004-2018)
- America's Top Doctors Award, Castle Connolly Medical Ltd. ((2015-2025))

- America's Top Doctors Award, Castle Connolly Medical Ltd. ((2014))

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Editorial Board, Kidney News, American Society of Nephrology (2010 - 2021)
- Glomerular Disease Adjunct Committee, American Society of Nephrology (2024 - present)
- Member, Glomerular Disease Advisory Committee, American Society of Nephrology (2013 - 2017)
- Member (ex-officio), Communications Committee, American Society of Nephrology (2015 - present)

PROFESSIONAL EDUCATION

- Medical Education: New York Medical College (1985) NY
- Board Certification: Nephrology, American Board of Internal Medicine (2024)
- Fellowship: Stanford University School of Medicine (1992) CA
- Residency: Long Island Jewish Medical Center (1988) NY
- Board Certification: Internal Medicine, American Board of Internal Medicine (1988)
- Internship: Long Island Jewish Medical Center (1986) NY

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

We are continuing to grow a glomerulonephritis cohort study, including immunologic characterization. We have completed interventional studies of preeclampsia exploring the nitric oxide, endothelin system and effects on glomerular function and morphometry. We continue to recruit patients for treatment and observational studies of glomerular disease, including FSGS, membranous and particularly IgA nephropathy. We also are actively studying renal disease in systemic amyloidosis.

CLINICAL TRIALS

- A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy, Recruiting
- KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis, Recruiting
- Nephrotic Syndrome Study Network, Recruiting
- Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN), Recruiting
- Transformative Research in Diabetic Nephropathy, Recruiting
- A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy, Not Recruiting
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis, Not Recruiting
- Atacicept in Subjects With IgA Nephropathy, Not Recruiting
- Atrasentan in Patients With IgA Nephropathy, Not Recruiting
- Atrasentan in Patients With Proteinuric Glomerular Diseases, Not Recruiting
- Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN), Not Recruiting
- Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN), Not Recruiting
- HI-Bio, Not Specified
- Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy, Not Specified

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Medicine (Masters Program)

Publications

PUBLICATIONS

- **A plain language summary: long-term safety and effectiveness of atacept in individuals with IgA nephropathy.** *Current medical research and opinion*
Barratt, J., Chen, K., Lafayette, R.
2026; 1-15
- **Complement-Mediated Kidney Diseases: Role of Alternative Pathway in Glomerular Inflammation.** *Kidney international reports*
Barratt, J., Garred, P., Lafayette, R. A., Zhang, H., Floege, J.
2026; 11 (2): 103705
- **Current trial landscape of IgA nephropathy therapy.** *Med (New York, N.Y.)*
Kim, J., Kamal, F., Lafayette, R.
2026; 7 (1): 100940
- **Modern Challenges in Infection Prevention: Encapsulated Organisms in the era of novel complement inhibitors.** *Kidney international*
Al Jurdi, A., Kotton, C. N., Lafayette, R.
2025
- **Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial** *KIDNEY INTERNATIONAL REPORTS*
Perkovic, V., Barratt, J., Lafayette, R., Liew, A., Suzuki, Y., Carroll, K., Cheung, C., Tesar, V., Trimarchi, H., Wong, M., Zhang, H., Xia, J., Fajardo, et al
2025; 10 (12): 4207-4218
- **A Phase 3 Trial of Atacept in Patients with IgA Nephropathy.** *The New England journal of medicine*
Lafayette, R., Barbour, S. J., Brenner, R. M., Campbell, K. N., Doan, T., Eren, N., Floege, J., Jha, V., Kim, B. S., Liew, A., Maes, B., Pal, A., Pecoits-Filho, et al
2025
- **TESTING for the Best Biomarker in IgA Nephropathy.** *Clinical journal of the American Society of Nephrology : CJASN*
Lafayette, R. A.
2025
- **ALIGN post-hoc analyses: Reduction in proteinuria with atrasentan across subgroups by MEST-C score, baseline hematuria and baseline UPCR**
Heerspink, H. J. L., Jardine, M., Kohan, D., Lafayette, R., Levin, A., Liew, A., Zhang, H., Davies, H., Knorr, B., Ansari, S., Renfurm, R., Barratt, J.
OXFORD UNIV PRESS.2025: I910-I911
- **Efficacy of Acthar gel and Tacrolimus in DNA-JB9 Positive Fibrillary Glomerulopathy** *KIDNEY INTERNATIONAL REPORTS*
Tumlin, J. A., Podoll, A., Kopyt, N., Rovin, B., Lafayette, R., Bomback, A., Glassock, R., Whitson, J., Press, A., Appel, G. B.
2025; 10 (9): 3128-3137
- **A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF CB-010, A NEXT-GENERATION CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR-T CELL THERAPY, IN PATIENTS WITH REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (GALLOP)**
Chatham, W., Fiorenza, S., Weinmann-Menke, J., Sanchez-Pernaute, O., Lafayette, R., Askanase, A., Gerber, M., Alexander, L., Mao, P., Garner, E., Kwong, G., Fowler, T., Kufeldt, et al
J RHEUMATOL PUBL CO.2025: 147-148
- **Expert Discussion on Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Challenges and Considerations.** *Advances in therapy*
Lafayette, R. A., Charu, V., Glassock, R. J.
2025

- **Authors' Reply: Complement Inhibition Therapy in IgA Nephropathy: Total or Selective Inhibition?** *Journal of the American Society of Nephrology : JASN*
Barratt, J., Garlo, K., Kateifides, A., Lafayette, R.
2025
- **Active glomerular inflammation versus chronicity and fibrosis: The role of targeted therapies in IgA nephropathy.** *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*
Radhakrishnan, J., Lafayette, R. A.
2025
- **Current Biomarkers of IgA Nephropathy.** *Seminars in nephrology*
Kamal, F., Kim, J., Lafayette, R.
2025: 151572
- **Clinical Outcomes in the Nephrotic Syndrome Study Network: Disease Burden and Treatment Patterns over Time.** *Glomerular diseases*
Drexler, Y., Athavale, A., Smith, A. R., Liu, Q., Zee, J., Mariani, L. H., Lafayette, R. A., NEPTUNE Clinical Outcomes Working Group
2025; 5 (1): 288-303
- **Long-Term Results from an Open-Label Extension Study of Ataccept for the Treatment of IgA Nephropathy.** *Journal of the American Society of Nephrology : JASN*
Barratt, J., Barbour, S., Brenner, R., Cooper, K., Wei, X., Eren, N., Floege, J., Jha, V., Kim, S. G., Maes, B., Phoon, R. K., Singh, H., Tesař, et al
2024
- **Atrasentan in Patients with IgA Nephropathy.** *The New England journal of medicine*
Heerspink, H. J., Jardine, M., Kohan, D. E., Lafayette, R. A., Levin, A., Liew, A., Zhang, H., Lodha, A., Gray, T., Wang, Y., Renfurm, R., Barratt, J.
2024
- **Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial.** *Journal of the American Society of Nephrology : JASN*
Lafayette, R., Tumlin, J., Fenoglio, R., Kaufeld, J., Pérez Valdivia, M. A., Wu, M. S., Susan Huang, S. H., Alamartine, E., Kim, S. G., Yee, M., Kateifides, A., Rice, K., Garlo, et al
2024
- **Clinical and Humanistic Burden of IgAN in Adult Patients: A Global Real-World Survey.** *Kidney360*
Tang, S. C., Wei, C., Aldworth, C., George, A. T., Kattlun, J., Tomas, G. R., Kroes, M., Roccatello, D., Przybysz, R., Smeets, S., Golden, K., Garratt-Wheeldon, J., Chatterton, et al
2024
- **Safety and Efficacy of Avacopan in Patients with C3 Glomerulopathy: Randomized, Double-Blind Clinical Trial.** *Journal of the American Society of Nephrology : JASN*
Bomback, A. S., Herlitz, L. C., Kedia, P. P., Petersen, J., Yue, H., Lafayette, R. A.
2024
- **Efficacy and Safety of Nefecon in Patients with Immunoglobulin A Nephropathy from Mainland China: 2-Year NeflgArd Trial Results.** *Kidney360*
Zhang, H., Lafayette, R., Wang, B., Ying, L., Zhu, Z., Stone, A., Kristensen, J., Barratt, J.
2024
- **Deconvolution of Human Urine across the Transcriptome and Metabolome.** *Clinical chemistry*
Vorperian, S. K., DeFelice, B. C., Buonomo, J. A., Chinchinian, H. J., Gray, I. J., Yan, J., Mach, K. E., La, V., Lee, T. J., Liao, J. C., Lafayette, R., Loeb, G. B., Bertozzi, et al
2024
- **Utilizing complement inhibition in IgA nephropathy.** *Nephrology (Carlton, Vic.)*
Lafayette, R.
2024; 29 Suppl 2: 44-46
- **Targeting APRIL in the treatment of glomerular diseases.** *Kidney international*
Cheung, C. K., Barratt, J., Lafayette, R., Liew, A., Suzuki, Y., Tesar, V., Trimarchi, H., Wong, M. G., Zhang, H., Rizk, D. V.
2024

- **Therapy of IgA nephropathy: time for a paradigm change.** *Frontiers in medicine*
Barratt, J., Lafayette, R. A., Floege, J.
2024; 11: 1461879
- **Stop Sitting on Our "RAASes": Get Moving with the Most Effective Care for Our Patients.** *Journal of the American Society of Nephrology : JASN*
Lafayette, R.
2024
- **Preparation and Rationale for a Patient-Centered Clinical Outcome Assessment Set of Fluid Overload for Drug Development in Nephrotic Syndrome.** *Glomerular diseases*
Salmon, E., Carozzi, N. E., Lai, J. S., Spino, C., Wang, Y., Capellari, E., Scherr, R., Sifre, K., Sullivan, S., Hurt, C., Creguer, T., Helm, K., Lafayette, et al
2024; 4 (1): 172-182
- **Targeted release of budesonide in primary IgA nephropathy - Authors' reply.** *Lancet (London, England)*
Lafayette, R., Kristensen, J., Stone, A., Barratt, J.
2024; 403 (10446): 2786
- **Subgroup and secondary endpoint evaluation of a phase 2 randomized placebo-controlled trial of ravulizumab in IgA nephropathy**
Valdivia, M., Tumlin, J. A., Kaufeld, J., Wu, M., Lafayette, R., Barratt, J., Huang, S., Fenoglio, R., Kim, S., Rice, K., Katefides, A., Garlo, K., Alamartine, et al
OXFORD UNIV PRESS.2024
- **Felzartamab (anti-CD38) in patients with IgA Nephropathy-interim results from the IGNAZ study**
Floege, J., Lafayette, R., Barratt, J., Schwartz, B., Manser, P. T., Patel, U. D., Pineda, L., Faulhaber, N., Boxhammer, R., Haertle, S., Thakur, A., Barbour, S.
OXFORD UNIV PRESS.2024
- **A phase 3 randomized controlled trial of ravulizumab in adult patients with IgA nephropathy**
Trimarchi, H., Barratt, J., Heerspink, H., Inker, L., Bruchfeld, A., Zhang, H., Carroll, K., Suzuki, Y., Marsala, J., Schneider, B., Katefides, A., Rice, K., Garlo, et al
OXFORD UNIV PRESS.2024
- **Impact of atacept on hematuria in IGA nephropathy: post-hoc analysis of the phase 2b ORIGIN study**
Floege, J., Barratt, J., Maes, B., Cooper, K., Lin, C., Wei, X., Barbour, S., Phoon, R., Kim, S., Tesar, V., Jha, V., Wadhvani, S., Lafayette, et al
OXFORD UNIV PRESS.2024
- **Membranoproliferative Glomerulonephritis Pattern of Injury.** *Advances in kidney disease and health*
Yu, S. M., Deoliveira, M., Chung, M., Lafayette, R.
2024; 31 (3): 216-222
- **Felzartamab (anti-CD38) in patients with IgA Nephropathy-interim results from the IGNAZ study**
Floege, J., Lafayette, R., Barratt, J., Schwartz, B., Manser, P. T., Patel, U. D., Pineda, L., Faulhaber, N., Boxhammer, R., Haertle, S., Thakur, A., Barbour, S.
OXFORD UNIV PRESS.2024: I252-I253
- **Phase 2b ORIGIN study open label extension with atacept in patients with IgA nephropathy and persistent proteinuria: week 72 interim analysis**
Lafayette, R., Maes, B., Israni, R., Lin, C., Wei, X., Barbour, S., Phoon, R., Kim, S., Tesar, V., Floege, J., Jha, V., Barratt, J.
OXFORD UNIV PRESS.2024: I53-I55
- **Quality of life and fatigue burden in individuals living with Complement 3 Glomerulopathy - a real-world study**
Lafayette, R., Sidhu, R., Proudfoot, C., Pannagl, K., Ndife, B., Smeets, S., Murphy, K., Przybysz, R., Decourcy, J., Libby, S., Sinha, S.
OXFORD UNIV PRESS.2024: I2118-I2119
- **Impact of atacept on hematuria in IGA nephropathy: post-hoc analysis of the phase 2b ORIGIN study**
Floege, J., Barratt, J., Maes, B., Cooper, K., Lin, C., Wei, X., Barbour, S., Phoon, R., Kim, S., Tesar, V., Jha, V., Wadhvani, S., Lafayette, et al
OXFORD UNIV PRESS.2024: I710-I711
- **A phase 3 randomized controlled trial of ravulizumab in adult patients with IgA nephropathy**

- Trimarchi, H., Barratt, J., Heerspink, H., Inker, L., Bruchfeld, A., Zhang, H., Carroll, K., Suzuki, Y., Marsala, J., Schneider, B., Katefides, A., Rice, K., Garlo, et al
OXFORD UNIV PRESS.2024: I730-I732
- **Matching-adjusted indirect comparison of eGFR in patients with immunoglobulin A nephropathy treated with Nefecon (TRF budesonide) or sparsentan**
Reich, H., Patel, M., Kopiec, A., Fu, S., Hummel, N., Lafayette, R.
OXFORD UNIV PRESS.2024: I734-I735
 - **Subgroup and secondary endpoint evaluation of a phase 2 randomized placebo-controlled trial of ravulizumab in IgA nephropathy**
Perez Valdivia, M., Tumlin, J. A., Kaufeld, J., Wu, M., Lafayette, R., Barratt, J., Huang, S., Fenoglio, R., Kim, S., Rice, K., Katefides, A., Garlo, K., Alamartine, et al
OXFORD UNIV PRESS.2024: I714-I716
 - **Growth in children with nephrotic syndrome: a post hoc analysis of the NEPTUNE study.** *Pediatric nephrology (Berlin, Germany)*
Maniar, A., Gipson, D. S., Brady, T., Srivastava, T., Selewski, D. T., Greenbaum, L. A., Dell, K. M., Kaskel, F., Massengill, S., Tran, C., Trachtman, H., Lafayette, R., Almaani, et al
2024
 - **A Phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacept for treatment of IgA nephropathy.** *Kidney international*
Lafayette, R., Barbour, S., Israni, R., Wei, X., Eren, N., Floege, J., Jha, V., Kim, S. G., Maes, B., Phoon, R. K., Singh, H., Tesar, V., Lin, et al
2024
 - **Longitudinal analysis of blood pressure and lipids in childhood nephrotic syndrome.** *Pediatric nephrology (Berlin, Germany)*
Carboni, J., Thomas, E., Gipson, D. S., Brady, T. M., Srivastava, T., Selewski, D. T., Greenbaum, L. A., Wang, C., Dell, K. M., Kaskel, F., Massengill, S., Reidy, K., Tran, et al
2024
 - **Randomized Trial on the Effect of an Oral Spleen Tyrosine Kinase Inhibitor in the Treatment of IgA Nephropathy.** *Kidney international reports*
Tam, F. W., Tumlin, J., Barratt, J., Rovin, B. H., Roberts, I. S., Roufosse, C., Cook, H. T., Bhangal, G., Brown, A. L., Busch, M., Dudhiya, F., Duliege, A., Fraser, et al
2023; 8 (12): 2546-2556
 - **Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.** *Lancet (London, England)*
Rovin, B. H., Barratt, J., Heerspink, H. J., Alpers, C. E., Bieler, S., Chae, D., Diva, U. A., Floege, J., Gesualdo, L., Inrig, J. K., Kohan, D. E., Komers, R., Kooienga, et al
2023
 - **Cure Glomerulonephropathy Pathology Classification and Core Scoring Criteria, Reproducibility, and Clinicopathologic Correlations.** *Glomerular diseases*
Palmer, M. B., Royal, V., Jennette, J. C., Smith, A. R., Liu, Q., Ambruzs, J. M., Andeen, N. K., D'Agati, V. D., Fogo, A. B., Gaut, J., Gbadegesin, R. A., Greenbaum, L. A., Hou, et al
2023; 3 (1): 248-257
 - **Targeting APRIL in the Treatment of IgA Nephropathy.** *Clinical journal of the American Society of Nephrology : CJASN*
Cheung, C. K., Barratt, J., Carroll, K., Lafayette, R. A., Liew, A., Suzuki, Y., Tesar, V., Trimarchi, H., Wong, M. G., Zhang, H., Perkovic, V., Rizk, D. V.
2023
 - **Expert Discussion on Challenges in C3G Diagnosis: A Podcast Article on Best Practices in Kidney Biopsies.** *Advances in therapy*
Lafayette, R. A., Charu, V.
2023
 - **The Treatment of Primary IgA Nephropathy: Change, Change, Change.** *American journal of kidney diseases : the official journal of the National Kidney Foundation*
Caster, D. J., Lafayette, R. A.
2023
 - **The Significance of Hematuria in Podocytopathies.** *Clinical journal of the American Society of Nephrology : CJASN*
Marchel, D., Trachtman, H., Larkina, M., Helmuth, M., Lai Yee, J. Y., Fermin, D., Bomback, A. S., Canetta, P. A., Gipson, D. S., Mottl, A. K., Parekh, R. S., Saha, M. K., Sampson, et al

2023

- **The Association of Class I and II Human Leukocyte Antigen Serotypes With End-Stage Kidney Disease Due to Membranoproliferative Glomerulonephritis and Dense Deposit Disease.** *American journal of kidney diseases : the official journal of the National Kidney Foundation*
Afolabi, H., Zhang, B. M., O'Shaughnessy, M., Chertow, G. M., Lafayette, R., Charu, V.
2023
- **Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NeflgArd): 2-year results from a randomised phase 3 trial.** *Lancet (London, England)*
Lafayette, R., Kristensen, J., Stone, A., Floege, J., Tesar, V., Trimarchi, H., Zhang, H., Eren, N., Paliege, A., Reich, H. N., Rovin, B. H., Barratt, J.
2023
- **Considering the Treatment of IgA Nephropathy.** *Clinical journal of the American Society of Nephrology : CJASN*
Lafayette, R. A., S Kamal, F.
2023
- **Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy.** *Clinical journal of the American Society of Nephrology : CJASN*
Barbour, S. J., Fervenza, F. C., Induruwage, D., Brenchley, P. E., Rovin, B., Hladunewich, M., Reich, H. N., Lafayette, R., Aslam, N., Appel, G. B., Zand, L., Kiryluk, K., Liu, et al
2023
- **C3 GLOMERULOPATHY CURRENT THERAPY AND REAL-WORLD MANAGEMENT - INTERIM RESULTS FROM A MULTI-COUNTRY STUDY**
Proudfoot, C., Pannagl, K., Ndife, B., King, A., Murphy, K., Libby, S., Lafayette, R.
OXFORD UNIV PRESS.2023: I675
- **DIFFERENCES IN HEALTHCARE RESOURCE UTILIZATION FOR THE MANAGEMENT OF IMMUNOGLOBULIN A NEPHROPATHY IN EUROPE, THE US, CHINA AND JAPAN**
Kroes, M., Aldworth, C., George, A., Ndife, B., Prieto, L., Lafayette, R., De Courcy, J., Chatterton, E.
ELSEVIER SCIENCE INC.2023: S385
- **IMMUNOGLOBULIN A NEPHROPATHY PATIENT REPORTED HEALTH UTILITY AND QUALITY OF LIFE: EVIDENCE FROM REAL-WORLD DATA**
Lafayette, R., Aldworth, C., George, A., De Courcy, J., Golden, K., Kroes, M., Proudfoot, C., Ndife, B.
ELSEVIER SCIENCE INC.2023: S364
- **WORK, PRODUCTIVITY, AND ACTIVITY IMPAIRMENT IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY: RESULTS FROM A REAL-WORLD STUDY**
Lafayette, R., Aldworth, C., George, A., De Courcy, J., Garratt-Wheeldon, J., Ndife, B., Kroes, M.
ELSEVIER SCIENCE INC.2023: S385
- **REAL-WORLD SIGNS AND SYMPTOMS AT DIAGNOSIS IN PATIENTS WITH C3 GLOMERULOPATHY - INTERIM RESULTS FROM A MULTI-COUNTRY STUDY**
Proudfoot, C., Pannagl, K., Nguyen, J., King, A., Murphy, K., Decourcy, J., Lafayette, R.
OXFORD UNIV PRESS.2023: I536-I537
- **IMMUNOGLOBULIN A NEPHROPATHY: PATIENT-REPORTED SYMPTOMS PRIOR TO FIRST CONSULTATION AND DIAGNOSIS - RESULTS FROM A REAL-WORLD SURVEY**
Lafayette, R., Kroes, M., Kattlun, J., Aldworth, C., George, A., Decourcy, J., Chatterton, E.
OXFORD UNIV PRESS.2023: I556
- **ORIGIN TRIAL: 24-WK PRIMARY ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PH2B STUDY OF ATACICEPT IN PATIENTS WITH IGAN**
Lafayette, R., Maes, B., Lin, C., Barbour, S., Phoon, R., Kim, S., Tesar, V., Floege, J., Jha, V., Barratt, J.
OXFORD UNIV PRESS.2023: I23
- **IgA Nephropathy: the Lectin Pathway and Implications for Targeted Therapy.** *Kidney international*
Barratt, J., Lafayette, R. A., Zhang, H., Tesar, V., Rovin, B. H., Tumlin, J. A., Reich, H. N., Floege, J.
2023
- **Budesonide delayed-release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy.** *Expert review of clinical immunology*

Barratt, J., Lafayette, R. A., Rovin, B. H., Fellstrom, B.
2023

- **IMMUNOGLOBULIN A NEPHROPATHY PATIENT REPORTED HEALTH UTILITY AND QUALITY OF LIFE: EVIDENCE FROM US REAL-WORLD DATA**
Lafayette, R., Aldworth, C., George, A., de Courcy, J., Golden, K., Ndife, B., Kroes, M.
W B SAUNDERS CO-ELSEVIER INC.2023: S94
- **Class I and II Human Leukocyte Antigen Serotypes Associated with End-Stage Kidney Disease due to Membranoproliferative Glomerulonephritis and Dense Deposit Disease**
Afolabi, H., Zhang, B., O'Shaughnessy, M., Chertow, G., Lafayette, R., Charu, V.
ELSEVIER SCIENCE INC.2023: S1422-S1423
- **The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies.** *Frontiers in nephrology*
Cheung, C. K., Barratt, J., Liew, A., Zhang, H., Tesar, V., Lafayette, R.
2023; 3: 1346769
- **pSTAT1 Is Activated during the Progression of IgA Nephropathy.** *Glomerular diseases*
Tao, J., Kambham, N., Kwok, S., Lafayette, R. A.
2023; 3 (1): 12-18
- **One-Year estimated GFR Slope Independently Predicts Clinical Benefit in Immunoglobulin A Nephropathy.** *Kidney international reports*
Lafayette, R. A., Reich, H. N., Stone, A. M., Barratt, J.
2022; 7 (12): 2730-2733
- **Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis.** *Kidney international*
Mariani, L. H., Eddy, S., AlAkwa, F. M., McCown, P. J., Harder, J. L., Nair, V., Eichinger, F., Martini, S., Ademola, A. D., Boima, V., Reich, H. N., El Saghir, J., Godfrey, et al
2022
- **Results from part A of the multi-center, double-blind, randomized, placebo-controlled NeflgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.** *Kidney international*
Barratt, J., Lafayette, R., Kristensen, J., Stone, A., Cattran, D., Floege, J., Tesar, V., Trimarchi, H., Zhang, H., Eren, N., Paliege, A., Rovin, B. H., NeflgArd Trial Investigators
2022
- **Racial and Ethnic Disparities in Acute Care Utilization Among Patients With Glomerular Disease.** *American journal of kidney diseases : the official journal of the National Kidney Foundation*
Krissberg, J. R., O'Shaughnessy, M. M., Smith, A. R., Helmuth, M. E., Almaani, S., Aviles, D. H., Brathwaite, K. E., Cai, Y., Cattran, D., Gbadegesin, R., Glenn, D. A., Greenbaum, L. A., Iragorri, et al
2022
- **International Physicians Delphi Survey: Managing Patients With IgA Nephropathy.** *Kidney international reports*
Floege, J., Barratt, J., Coppo, R., Lafayette, R., Radhakrishnan, J., Reich, H. N., Rovin, B. H., Selewski, D. T., Vivarelli, M., Pham, C., Tesar, V.
2022; 7 (9): 2076-2080
- **Comparing Kidney Health Outcomes in Children, Adolescents, and Adults With Focal Segmental Glomerulosclerosis.** *JAMA network open*
Gipson, D. S., Troost, J. P., Spino, C., Attalla, S., Tarnoff, J., Massengill, S., Lafayette, R., Vega-Warner, V., Adler, S., Gipson, P., Elliott, M., Kaskel, F., Fermin, et al
2022; 5 (8): e2228701
- **C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study.** *Clinical kidney journal*
Bruchfeld, A., Magin, H., Nachman, P., Parikh, S., Lafayette, R., Potarca, A., Miao, S., Bekker, P.
2022; 15 (5): 922-928
- **REAL-WORLD SIGNS AND SYMPTOMS AT DIAGNOSIS IN PATIENTS WITH IGA NEPHROPATHY**
Roccatello, D., Kattlun, J., Przybysz, R., George, A., Aldworth, C., Proudfoot, C., Wang, W., Decourcy, J., Lafayette, R.
OXFORD UNIV PRESS.2022: 1159-1160
- **C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study** *CLINICAL KIDNEY JOURNAL*

Bruchfeld, A., Magin, H., Nachman, P., Parikh, S., Lafayette, R., Potarca, A., Miao, S., Bekker, P.
2022

- **A Focus Group Study of Self-Management in Patients With Glomerular Disease.** *Kidney international reports*
Carter, S. A., Teng, C., Gutman, T., Logeman, C., Cattran, D., Lightstone, L., Bagga, A., Barbour, S. J., Barratt, J., Boletis, J., Caster, D. J., Coppo, R., Fervenza, et al
1800; 7 (1): 56-67
- **A Core Outcome Set for Trials in Glomerular Disease A Report of the Standardized Outcomes in Nephrology?Glomerular Disease (SONG-GD) Stakeholder Workshops** *CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY*
Carter, S. A., Lightstone, L., Cattran, D., Tong, A., Bagga, A., Barbour, S. J., Barratt, J., Boletis, J., Caster, D. J., Coppo, R., Fervenza, F. C., Floege, J., Hladunewich, et al
2021
- **The Development and Use of an EHR-Linked Database for Glomerular Disease Research and Quality Initiatives.** *Glomerular diseases*
Eikstadt, R. N., Desmond, H. E., Lindner, C., Chen, L. Y., Courtlandt, C. D., Massengill, S. F., Kamil, E. S., Lafayette, R., Pesenson, A., Elliott, M., Gipson, P. E., Gipson, D. S.
2021; 1 (4): 173-179
- **Association between Psychiatric Disorders and Glomerular Disease.** *Glomerular diseases*
Desmond, H. E., Lindner, C., Troost, J. P., Held, Z., Callaway, A., Oh, G. J., Lafayette, R., O'Shaughnessy, M., Elliott, M., Adler, S. G., Kamil, E. S., Pesenson, A., Selewski, et al
2021; 1 (3): 118-128
- **Improving data quality in observational research studies: Report of the Cure Glomerulonephropathy (CureGN) network.** *Contemporary clinical trials communications*
Gillespie, B. W., Laurin, L., Zinsser, D., Lafayette, R., Marasa, M., Wenderfer, S. E., Vento, S., Poulton, C., Barisoni, L., Zee, J., Helmuth, M., Lugani, F., Kamel, et al
2021; 22: 100749
- **y A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY (THE ALIGN STUDY)**
Heerspink, H., Kohan, D., Lafayette, R., Levin, A., Zhang, H., Glicklich, A., Camargo, M., King, A., Barratt, J.
OXFORD UNIV PRESS.2021: 194
- **APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis.** *Pediatric nephrology (Berlin, Germany)*
Zee, J., McNulty, M. T., Hodgin, J. B., Zhdanova, O., Hingorani, S., Jefferson, J. A., Gibson, K. L., Trachtman, H., Fornoni, A., Dell, K. M., Reich, H. N., Bagnasco, S., Greenbaum, et al
2021
- **Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease.** *Kidney international*
Carter, S. A., Logeman, C. n., Howell, M. n., Cattran, D. n., Lightstone, L. n., Bagga, A. n., Barbour, S. J., Barratt, J. n., Boletis, J. n., Caster, D. J., Coppo, R. n., Fervenza, F. C., Floege, et al
2021
- **Racial-ethnic differences in health-related quality of life among adults and children with glomerular disease.** *Glomerular diseases*
Krissberg, J. R., Helmuth, M. E., Almaani, S., Cai, Y., Cattran, D., Chatterjee, D., Gbadegesin, R. A., Gibson, K. L., Glenn, D. A., Greenbaum, L. A., Iragorri, S., Jain, K., Khalid, et al
2021; 1 (3): 105-117
- **Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.** *American journal of kidney diseases : the official journal of the National Kidney Foundation*
Bomback, A. S., Appel, G. B., Gipson, D. S., Hladunewich, M. A., Lafayette, R., Nester, C. M., Parikh, S. V., Smith, R. J., Trachtman, H., Heeger, P. S., Ram, S., Rovin, B. H., Ali, et al
2021
- **Documentation of Reproductive Health Counseling Among Women With CKD: A Retrospective Chart Review.** *American journal of kidney diseases : the official journal of the National Kidney Foundation*
Okundaye, I. O., Stedman, M. R., Rhee, J. J., O'Shaughnessy, M., Lafayette, R. A.
2021

- **Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy.** *Kidney international reports*
Lafayette, R. A., Rovin, B. H., Reich, H. N., Tumlin, J. A., Floege, J., Barratt, J.
2020; 5 (11): 2032–41
- **Why Target the Gut to Treat IgA Nephropathy?** *Kidney international reports*
Barratt, J., Rovin, B. H., Cattran, D., Floege, J., Lafayette, R., Tesar, V., Trimarchi, H., Zhang, H., NeflgArd Study Steering Committee
2020; 5 (10): 1620–24
- **Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis.** *Kidney international reports*
Gipson, D. S., Hladunewich, M. A., Lafayette, R., Sedor, J. R., Rovin, B. H., Barbour, S. J., McMahon, A., Jennette, J. C., Nachman, P. H., Willette, R. N., Paglione, M., Gao, F., Ross Terres, et al
2020; 5 (8): 1228–39
- **MASP-2 inhibition as a potential strategy for the management of IgA nephropathy** *DRUGS OF THE FUTURE*
Barratt, J., Lafayette, R.
2020; 45 (6): 389–96
- **JAK-STAT Activity in Peripheral Blood Cells and Kidney Tissue in IgA Nephropathy.** *Clinical journal of the American Society of Nephrology : CJASN*
Tao, J., Mariani, L., Eddy, S., Maecker, H., Kambham, N., Mehta, K., Hartman, J., Wang, W., Kretzler, M., Lafayette, R. A.
2020
- **Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers.** *Clinical journal of the American Society of Nephrology : CJASN*
Carter, S. A., Gutman, T., Logeman, C., Cattran, D., Lightstone, L., Bagga, A., Barbour, S. J., Barratt, J., Boletis, J., Caster, D., Coppo, R., Fervenza, F. C., Floege, et al
2020
- **Facing the Vexing Problem of Recurrent FSGS after Kidney Transplantation.** *Clinical journal of the American Society of Nephrology : CJASN*
Lafayette, R. A.
2020
- **Organ responses with daratumumab therapy in previously treated AL amyloidosis.** *Blood advances*
Chung, A. n., Kaufman, G. P., Sidana, S. n., Eckhart, E. n., Schrier, S. L., Lafayette, R. A., Arai, S. n., Witteles, R. M., Liedtke, M. n.
2020; 4 (3): 458–66
- **An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression.** *Kidney international reports*
Zand, L., Canetta, P., Lafayette, R., Aslam, N., Jan, N., Sethi, S., Fervenza, F. C.
2020; 5 (1): 58–65
- **Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study** *KIDNEY INTERNATIONAL*
Townsend, R. R., Guarnieri, P., Argyropoulos, C., Blady, S., Boustany-Kari, C. M., Devalaraja-Narashimha, K., Morton, L., Mottl, A. K., Patel, U., Palmer, M., Ross, M. J., Sarov-Blat, L., Steinbugler, et al
2020; 97 (1): 10–13
- **An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression** *KIDNEY INTERNATIONAL REPORTS*
Zand, L., Canetta, P., Lafayette, R., Aslam, N., Jan, N., Sethi, S., Fervenza, F. C.
2020; 5 (1): 58–65
- **The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network.** *Clinical kidney journal*
Troost, J. P., Waldo, A. n., Carlozzi, N. E., Murphy, S. n., Modersitzki, F. n., Trachtman, H. n., Nachman, P. H., Reidy, K. J., Selewski, D. T., Herreshoff, E. G., Srivastava, T. n., Gibson, K. L., Derebail, et al
2020; 13 (4): 597–606
- **Time to Initiation of Antihypertensive Therapy After Onset of Elevated Blood Pressure in Patients With Primary Proteinuric Kidney Disease.** *Kidney medicine*
Weaver, D. J., Waldo, A. n., Oh, G. J., Kamil, E. S., Elliott, M. n., Adler, S. n., Pesenson, A. n., Modes, M. M., Gipson, P. n., Lafayette, R. A., Selewski, D. T., Attalla, S. E., Eikstadt, et al

2020; 2 (2): 131–38

- **Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis**
Chung, A., Kaufman, G. P., Sidana, S., Eckhert, E., Schrier, S., Arai, S., Lafayette, R., Witteles, R., Liedtke, M.
AMER SOC HEMATOLOGY.2019
- **Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses**
Chung, A., Kaufman, G. P., Sidana, S., Iberri, D., Eckhert, E., Schrier, S., Lafayette, R., Arai, S., Witteles, R., Liedtke, M.
AMER SOC HEMATOLOGY.2019
- **Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease.** *Kidney international reports*
Oh, G. J., Waldo, A., Paez-Cruz, F., Gipson, P. E., Pesenson, A., Selewski, D. T., Kamil, E. S., Massengill, S. F., Lafayette, R. A., Modes, M., Adler, S. G., Desmond, H., Eikstadt, et al
2019; 4 (11): 1608-1616
- **Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease** *KIDNEY INTERNATIONAL REPORTS*
Oh, G. J., Waldo, A., Paez-Cruz, F., Gipson, P. E., Pesenson, A., Selewski, D. T., Kamil, E. S., Massengill, S. F., Lafayette, R. A., Modes, M., Adler, S. G., Desmond, H., Eikstadt, et al
2019; 4 (11): 1608–16
- **INTERIM RESULTS FROM AN ONGOING PHASE 2 STUDY EVALUATING THE USE OF A MASP-2 INHIBITOR FOR THE TREATMENT OF IGA NEPHROPATHY (IGAN)**
Barratt, J., Leifke, E., Whitaker, S., DeTulleo, L., Lafayette, R.
OXFORD UNIV PRESS.2019
- **Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease.** *Kidney international*
Carter, S. A., Lightstone, L., Cattran, D., Bagga, A., Barbour, S. J., Barratt, J., Boletis, J., Caster, D., Coppo, R., Fervenza, F. C., Floege, J., Hladunewich, M., Hogan, et al
2019; 95 (6): 1280–83
- **Plasma Zonulin Levels in Childhood Nephrotic Syndrome** *FRONTIERS IN PEDIATRICS*
Trachtman, H., Gipson, D. S., Lemley, K. V., Troost, J. P., Faul, C., Morrison, D. J., Vento, S. M., Ahn, D., Goldberg, J. D., Sedor, J., Dell, K., Schachere, M., Lemley, et al
2019; 7
- **Health-related quality of life in glomerular disease** *KIDNEY INTERNATIONAL*
Canetta, P. A., Troost, J. P., Mahoney, S., Kogon, A. J., Carlozzi, N., Bartosh, S. M., Cai, Y., Davis, T., Fernandez, H., Fornoni, A., Gbadegesin, R. A., Herreshoff, E., Mahan, et al
2019; 95 (5): 1209–24
- **Cause of kidney disease and cardiovascular events in a national cohort of US patients with end-stage renal disease on dialysis: a retrospective analysis** *EUROPEAN HEART JOURNAL*
O'Shaughnessy, M. M., Liu, S., Montez-Rath, M. E., Lafayette, R. A., Winkelmayr, W. C.
2019; 40 (11): 887-+
- **CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease** *AMERICAN JOURNAL OF KIDNEY DISEASES*
Mariani, L. H., Bomback, A. S., Canetta, P. A., Flessner, M. F., Helmuth, M., Hladunewich, M. A., Hogan, J. J., Kiryluk, K., Nachman, P. H., Nast, C. C., Rheault, M. N., Rizk, D., Trachtman, et al
2019; 73 (2): 218–29
- **Organoid single cell profiling identifies a transcriptional signature of glomerular disease** *JCI INSIGHT*
Harder, J. L., Menon, R., Otto, E. A., Zhou, J., Eddy, S., Wys, N. L., O'Connor, C., Luo, J., Nair, V., Cebrian, C., Spence, J. R., Bitzer, M., Troyanskaya, et al
2019; 4 (1)
- **A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis.** *JACC. Heart failure*
Barrett, C. D., Dobos, K. n., Liedtke, M. n., Tuzovic, M. n., Haddad, F. n., Kobayashi, Y. n., Lafayette, R. n., Fowler, M. B., Arai, S. n., Schrier, S. n., Witteles, R. M.
2019

- **Increasing Options for First-Line Therapy in Primary FSGS?** *KIDNEY INTERNATIONAL REPORTS*
Lafayette, R. A.
2019; 4 (1): 8-10
- **Noninvasive Urinary Monitoring of Progression in IgA Nephropathy.** *International journal of molecular sciences*
Yang, J. Y., Sarwal, R. D., Fervenza, F. C., Sarwal, M. M., Lafayette, R. A.
2019; 20 (18)
- **Increasing Options for First-Line Therapy in Primary FSGS?** *Kidney international reports*
Lafayette, R. A.
2019; 4 (1): 8–10
- **Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.** *The New England journal of medicine*
Fervenza, F. C., Appel, G. B., Barbour, S. J., Rovin, B. H., Lafayette, R. A., Aslam, N. n., Jefferson, J. A., Gipson, P. E., Rizk, D. V., Sedor, J. R., Simon, J. F., McCarthy, E. T., Brenchley, et al
2019; 381 (1): 36–46
- **Grading cardiac response in AL amyloidosis: implications for relapse and survival.** *British journal of haematology*
Eckhart, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., O'Shaughnessy, M., Liedtke, M.
2018
- **A rare case of Alport syndrome, atypical hemolytic uremic syndrome and Pauci-immune crescentic glomerulonephritis.** *BMC nephrology*
Tao, J., Lieberman, J., Lafayette, R. A., Kambham, N.
2018; 19 (1): 355
- **A rare case of Alport syndrome, atypical hemolytic uremic syndrome and Pauci-immune crescentic glomerulonephritis** *BMC NEPHROLOGY*
Tao, J., Lieberman, J., Lafayette, R. A., Kambham, N.
2018; 19
- **Graded Cardiac Response Correlates with Relapse and Survival in AL Amyloidosis**
Eckhart, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., O'Shaughnessy, M., Liedtke, M.
AMER SOC HEMATOLOGY.2018
- **Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study** *KIDNEY INTERNATIONAL REPORTS*
Selewski, D. T., Ambruzs, J. M., Appel, G. B., Bomback, A. S., Matar, R., Cai, Y., Cattran, D. C., Chishti, A. S., D'Agati, V. D., D'Alessandri-Silva, C. J., Gbadegesin, R. A., Hogan, J. J., Iragorri, et al
2018; 3 (6): 1373–84
- **JAK-STAT signaling is activated in the kidney and peripheral blood cells of patients with focal segmental glomerulosclerosis** *KIDNEY INTERNATIONAL*
Tao, J., Mariani, L., Eddy, S., Maecker, H., Kambham, N., Mehta, K., Hartman, J., Wang, W., Kretzler, M., Lafayettet, R. A.
2018; 94 (4): 795-808
- **JAK-STAT signaling is activated in the kidney and peripheral blood cells of patients with focal segmental glomerulosclerosis.** *Kidney international*
Tao, J., Mariani, L., Eddy, S., Maecker, H., Kambham, N., Mehta, K., Hartman, J., Wang, W., Kretzler, M., Lafayette, R. A.
2018
- **Cause of kidney disease and cardiovascular events in a national cohort of US patients with end-stage renal disease on dialysis: a retrospective analysis.** *European heart journal*
O'Shaughnessy, M. M., Liu, S., Montez-Rath, M. E., Lafayette, R. A., Winkelmayer, W. C.
2018
- **NephCure Accelerating Cures Institute: A Multidisciplinary Consortium to Improve Care for Nephrotic Syndrome** *KIDNEY INTERNATIONAL REPORTS*
Gipson, D. S., Selewski, D. T., Massengill, S. F., Modes, M., Desmond, H., Lee, L., Kamil, E., Elliott, M. R., Adler, S. G., Oh, G., Lafayette, R. A., Gipson, P. E., Sinha, et al
2018; 3 (2): 439–46

- **NephCure Accelerating Cures Institute: A Multidisciplinary Consortium to Improve Care for Nephrotic Syndrome.** *Kidney international reports*
Gipson, D. S., Selewski, D. T., Massengill, S. F., Modes, M. M., Desmond, H., Lee, L., Kamil, E., Elliott, M. R., Adler, S. G., Oh, G., Lafayette, R. A., Gipson, P. E., Sinha, et al
2018; 3 (2): 439-446
- **Immunoglobulin A Nephropathy: Advances in Understanding of Pathogenesis and Treatment.** *American journal of nephrology*
Lafayette, R. A., Kelepouris, E.
2018; 47 Suppl 1: 43-52
- **Immunoglobulin A Nephropathy: Advances in Understanding of Pathogenesis and Treatment** *AMERICAN JOURNAL OF NEPHROLOGY*
Lafayette, R. A., Kelepouris, E.
2018; 47: 43-52
- **Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis** *BLOOD*
Kaufman, G. P., Schrier, S. L., Lafayette, R. A., Arai, S., Witteles, R. M., Liedtke, M.
2017; 130 (7): 900-902
- **Corticosteroids for IgA Nephropathy: TESTING for Benefit, Discovering Harm.** *JAMA*
O'Shaughnessy, M. M., Lafayette, R. A.
2017; 318 (5): 429-431
- **C5A RECEPTOR INHIBITOR AVACOPAN IN IGA NEPHROPATHY STUDY**
Bruchfeld, A., Nachman, P., Parikh, S., Lafayette, R., Potarca, A., Diehl, J., Lohr, L., Miao, S., Schall, T., Bekker, P.
OXFORD UNIV PRESS.2017
- **A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction** *JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY*
Lafayette, R. A., Canetta, P. A., Ravin, B. H., Appel, G. B., Novak, J., Nath, K. A., Sethi, S., Tumlin, J. A., Mehta, K., Hogan, M., Erickson, S., Julian, B. A., Leung, et al
2017; 28 (4): 1306-1313
- **Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure.** *Journal of managed care & specialty pharmacy*
Rafique, Z., Weir, M. R., Onuigbo, M., Pitt, B., Lafayette, R., Butler, J., Lopes, M., Farnum, C., Peacock, W. F.
2017; 23 (4-a): S10-S19
- **Validating identification of patients with small vessel vasculitis, with or without renal involvement, using administrative healthcare records.** *Clinical nephrology*
O'Shaughnessy, M. M., Cheng, X. S., Montez-Rath, M. E., Lafayette, R. A., Winkelmayer, W. C.
2017; 87 (2017) (3): 159-162
- **Kidney Transplantation Rates Across Glomerulonephritis Subtypes in the United States.** *Transplantation*
O'Shaughnessy, M. M., Liu, S., Montez-Rath, M. E., Lafayette, R. A., Winkelmayer, W. C.
2017
- **Kidney Transplantation Outcomes across GN Subtypes in the United States** *JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY*
O'Shaughnessy, M. M., Liu, S., Montez-Rath, M. E., Lenihan, C. R., Lafayette, R. A., Winkelmayer, W. C.
2017; 28 (2): 632-644
- **Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry).** *The American journal of cardiology*
Tuzovic, M. n., Kobayashi, Y. n., Wheeler, M. n., Barrett, C. n., Liedtke, M. n., Lafayette, R. n., Schrier, S. n., Haddad, F. n., Witteles, R. n.
2017; 120 (8): 1381-86
- **Hematologic Responses and Cardiac Organ Improvement in Patients with Heavily Pretreated Cardiac Immunoglobulin Light Chain (AL) Amyloidosis Receiving Daratumumab**
Kaufman, G., Witteles, R., Wheeler, M., Ulloa, P., Lugtu, M., Arai, S., Schrier, S., Lafayette, R., Liedtke, M.
AMER SOC HEMATOLOGY.2016

- **DIFFERENCES IN PATIENT AND ALLOGRAFT SURVIVAL FOLLOWING KIDNEY TRANSPLANTATION AMONG GLOMERULONEPHRITIS SUBTYPES IN THE UNITED STATES.**
O'Shaughnessy, M., Montez-Rath, M., Liu, S., Lafayette, R., Winkelmayer, W.
W B SAUNDERS CO-ELSEVIER INC.2016: A82
- **Differences in Initial Hemodialysis Vascular Access Use Among Glomerulonephritis Subtypes in the United States** *AMERICAN JOURNAL OF KIDNEY DISEASES*
O'Shaughnessy, M. M., Montez-Rath, M. E., Zheng, Y., Lafayette, R. A., Winkelmayer, W. C.
2016; 67 (4): 638-647
- **Differences in initial treatment modality for end-stage renal disease among glomerulonephritis subtypes in the USA.** *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*
O'Shaughnessy, M. M., Montez-Rath, M. E., Lafayette, R. A., Winkelmayer, W. C.
2016; 31 (2): 290-298
- **Complete Remission in the Nephrotic Syndrome Study Network** *CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY*
Gipson, D. S., Troost, J. P., Lafayette, R. A., Hladunewich, M. A., Trachtman, H., Gadegbeku, C. A., Sedor, J. R., Holzman, L. B., Moxey-Mims, M. M., Perumal, K., Kaskel, F. J., Nelson, P. J., Tuttle, et al
2016; 11 (1): 81-89
- **Endoplasmic Reticulum Stress Predicts Clinical Response to Cyclosporine Treatment in Primary Membranous Nephropathy** *AMERICAN JOURNAL OF NEPHROLOGY*
Tao, J., Zhang, W., Wen, Y., Sun, Y., Chen, L., Li, H., Li, M., Li, X., Lafayette, R. A., Li, X.
2016; 43 (5): 348-356
- **Clinicopathological features of membranoproliferative glomerulonephritis under a new classification** *CLINICAL NEPHROLOGY*
Nargund, P., Kambham, N., Mehta, K., Lafayette, R. A.
2015; 84 (6): 323-330
- **Patient Characteristics and Outcomes by GN Subtype in ESRD.** *Clinical journal of the American Society of Nephrology*
O'Shaughnessy, M. M., Montez-Rath, M. E., Lafayette, R. A., Winkelmayer, W. C.
2015; 10 (7): 1170-1178
- **Red blood cell transfusion, hyperkalemia, and heart failure in advanced chronic kidney disease** *PHARMACOEPIDEMIOLOGY AND DRUG SAFETY*
Gill, K., Fink, J. C., Gilbertson, D. T., Monda, K. L., Muntner, P., Lafayette, R. A., Petersen, J., Chertow, G. M., Bradbury, B. D.
2015; 24 (6): 654-662
- **Mapping novel immunogenic epitopes in IgA nephropathy.** *Clinical journal of the American Society of Nephrology*
Woo, S. H., Sigdel, T. K., Dinh, V. T., Vu, M., Sarwal, M. M., Lafayette, R. A.
2015; 10 (3): 372-381
- **Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era.** *American journal of transplantation*
Davis, M. K., Kale, P., Liedtke, M., Schrier, S., Arai, S., Wheeler, M., Lafayette, R., Coakley, T., Witteles, R. M.
2015; 15 (3): 650-658
- **A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR)** *NEPHRON*
Fervenza, F. C., Canetta, P. A., Barbour, S. J., Lafayette, R. A., Rovin, B. H., Aslam, N., Hladunewich, M. A., Irazabal, M. V., Sethi, S., Gipson, D. S., Reich, H. N., Brenchley, P., Kretzler, et al
2015; 130 (3): 159-168
- **Correlation of urine protein-creatinine ratios and 24-hour urinary excretion in twin pregnancies**
Osmundson, S., Lafayette, R., Bowen, R., Roque, V., Aziz, N.
MOSBY-ELSEVIER.2015: S124-S125
- **Maternal proteinuria in twin compared with singleton pregnancies.** *Obstetrics and gynecology*
Osmundson, S. S., Lafayette, R. A., Bowen, R. A., Roque, V. C., Garabedian, M. J., Aziz, N.
2014; 124 (2): 332-337
- **Anemia Management Trends in Hospital-Based Dialysis Centers (HBDCs), 2010 to 2013.** *Clinical therapeutics*

- Coritsidis, G. N., Maglinte, G. A., Acharya, A., Saxena, A., Chang, C., Hill, J., Gitlin, M., Lafayette, R. A.
2014; 36 (3): 408-418
- **Renal function in normal and disordered pregnancy** *CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION*
Hussein, W., Lafayette, R. A.
2014; 23 (1): 46-53
 - **Urinary protein excretion in non-hypertensive twin pregnancies**
Osmundson, S., Roque, V., Bowen, R., Garabedian, M., Lafayette, R., Aziz, N.
MOSBY-ELSEVIER.2014: S379-S380
 - **Incidence and Relevance of Proteinuria in Bevacizumab-Treated Patients: Pooled Analysis from Randomized Controlled Trials** *AMERICAN JOURNAL OF NEPHROLOGY*
Lafayette, R. A., McCall, B., Li, N., Chu, L., Werner, P., Das, A., Glassock, R.
2014; 40 (1): 75-83
 - **Immunoglobulin A nephropathy: insights and progress.** *Translational research*
Lafayette, R. A.
2014; 163 (1): 3-7
 - **Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis** *HEART RHYTHM*
Varr, B. C., Zarafshar, S., Coakley, T., Liedtke, M., Lafayette, R. A., Arai, S., Schrier, S. L., Witteles, R. M.
2014; 11 (1): 158-162
 - **Treatment of Idiopathic FSGS with Adrenocorticotropic Hormone Gel** *CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY*
Hogan, J., Bomback, A. S., Mehta, K., Canetta, P. A., Rao, M. K., Appel, G. B., Radhakrishnan, J., Lafayette, R. A.
2013; 8 (12): 2072-2081
 - **High-potency statins and acute kidney injury-associated hospitalizations.** *American journal of kidney diseases*
Lenihan, C. R., Lafayette, R. A.
2013; 62 (5): 877-879
 - **Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.** *Haematologica*
Dinner, S., Witteles, W., Afghahi, A., Witteles, R., Arai, S., Lafayette, R., Schrier, S. L., Liedtke, M.
2013; 98 (10): 1593-1599
 - **Red blood cell transfusion use in patients with chronic kidney disease** *NEPHROLOGY DIALYSIS TRANSPLANTATION*
Gill, K. S., Muntner, P., Lafayette, R. A., Petersen, J., Fink, J. C., Gilbertson, D. T., Bradbury, B. D.
2013; 28 (6): 1504-1515
 - **The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis** *BRITISH JOURNAL OF HAEMATOLOGY*
Dinner, S., Witteles, W., Witteles, R., Lam, A., Arai, S., Lafayette, R., George, T. I., Schrier, S. L., Liedtke, M.
2013; 161 (3): 367-372
 - **Renal Physiology of Pregnancy** *ADVANCES IN CHRONIC KIDNEY DISEASE*
Cheung, K. L., Lafayette, R. A.
2013; 20 (3): 209-214
 - **INCIDENCE AND RELEVANCE OF PROTEINURIA IN BEVACIZUMAB (BV)-TREATED PATIENTS (PTS): POOLED ANALYSIS FROM RANDOMIZED CONTROLLED TRIALS (RCTS)** *37th Congress of the European-Society-for-Medical-Oncology (ESMO)*
Lafayette, R., McCall, B., Li, N. F., Chu, L., Werner, P., Das, A., Glassock, R. J.
OXFORD UNIV PRESS.2012: 171-171
 - **More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis** *ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY*
Stevenson, R., Witteles, R., Damrose, E., Arai, S., Lafayette, R. A., Schrier, S., Afghahi, A., Liedtke, M.
2012; 138 (5): 509-511

- **ADRENOCORTICOTROPIN HORMONE (ACTH) FOR THE TREATMENT OF PRIMARY FOCAL GLOMERULOSCLEROSIS (FSGS)** *Spring Clinical Meeting of the National-Kidney-Foundation*
Lafayette, R. A., Root, C., Mehta, K.
W B SAUNDERS CO-ELSEVIER INC.2012: A49–A49
- **Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies** *JOURNAL OF HEART AND LUNG TRANSPLANTATION*
Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., Witteles, R. M.
2012; 31 (3): 325-331
- **Profiling of Autoantibodies in IgA Nephropathy, an Integrative Antibiomics Approach** *CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY*
Sigdel, T. K., Woo, S. H., Dai, H., Khatri, P., Li, L., Myers, B., Sarwal, M. M., Lafayette, R. A.
2011; 6 (12): 2775-2784
- **Cardiac Amyloidosis: Screening Criteria for Heart Transplantation and New Strategies for Post-Transplant Therapy** *15th Annual Scientific Meeting of the Heart-Failure-Society-of-America*
Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., Witteles, R. M.
CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS.2011: S45–S46
- **Serum relaxin levels and kidney function in late pregnancy with or without preeclampsia** *CLINICAL NEPHROLOGY*
Lafayette, R. A., Hladunewich, M. A., Derby, G., Blouch, K., Druzyn, M. L., Myers, B. D.
2011; 75 (3): 226-232
- **A Pilot Study of Melphalan, Lenalidomide and Dexamethasone In AL Amyloidosis: Interim Results** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Afghahi, A., Witteles, W., Witteles, R., Liedtke, M., Lafayette, R., Arai, S., Schrier, S. L.
AMER SOC HEMATOLOGY.2010: 810–11
- **AL Amyloidosis and Concomitant Myeloma: Time to Reconsider Assumptions.**
Witteles, W., Witteles, R., Liedtke, M., Arai, S., Lafayette, R., George, T. I., Schrier, S. L.
AMER SOC HEMATOLOGY.2010: 1649
- **Hemoglobinuria and Acute Kidney Injury Requiring Hemodialysis Following Intravenous Immunoglobulin Infusion** *AMERICAN JOURNAL OF KIDNEY DISEASES*
Welles, C. C., Tamba, S., Lafayette, R. A.
2010; 55 (1): 148-151
- **Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients** *40th Annual Meeting of the American-Society-of-Nephrology/Annual Renal Week*
Chan, K., Moran, J., Hlatky, M., Lafayette, R.
OXFORD UNIV PRESS.2009: 1956–62
- **Imatinib in the Treatment of Nephrogenic Systemic Fibrosis** *AMERICAN JOURNAL OF KIDNEY DISEASES*
Chandran, S., Petersen, J., Jacobs, C., Forentino, D., Doeden, K., Lafayette, R. A.
2009; 53 (1): 129-132
- **Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients** *NEPHROLOGY DIALYSIS TRANSPLANTATION*
Chan, K. E., Lafayette, R. A., Whittemore, A. S., Hlatky, M. A., Moran, J.
2008; 23 (9): 2948-2956
- **Course of preeclamptic glomerular injury after delivery** *AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY*
Hladunewich, M. A., Myers, B. D., Derby, G. C., Blouch, K. L., Druzyn, M. L., Deen, W. M., Naimark, D. M., Lafayette, R. A.
2008; 294 (3): F614-F620
- **Prediction of early progression in recently diagnosed IgA nephropathy** *NEPHROLOGY DIALYSIS TRANSPLANTATION*
Lemley, K. V., Lafayette, R. A., Derby, G., Blouch, K. L., Anderson, L., Efron, B., Myers, B. D.
2008; 23 (1): 213-222
- **Pathophysiology of the clinical manifestations of preeclampsia** *CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY*

- Hladunewich, M., Karumanchi, S. A., Lafayette, R.
2007; 2 (3): 543-549
- **Effect of L-arginine therapy on the glomerular injury of preeclampsia: a randomized controlled trial.** *Obstetrics and gynecology*
Hladunewich, M. A., Derby, G. C., Lafayette, R. A., Blouch, K. L., Druzin, M. L., Myers, B. D.
2006; 107 (4): 886-895
 - **Effect of L-arginine therapy on the glomerular injury of preeclampsia - A randomized controlled trial** *OBSTETRICS AND GYNECOLOGY*
Mladunewich, M. A., Derby, G. C., Lafayette, R. A., Blouch, K. L., Druzin, M. L., Myers, B. D.
2006; 107 (4): 886-895
 - **Associations of serologic markers of infection and inflammation with vascular disease events and mortality in American dialysis patients.** *Clinical and experimental nephrology*
Lentine, K. L., Parsonnet, J., Taylor, I., Wrone, E. M., Lafayette, R. A.
2006; 10 (1): 55-62
 - **Renal tubular injury associated with anagrelide** *NEPHROLOGY DIALYSIS TRANSPLANTATION*
Rodwell, G. E., Troxell, M. L., Lafayette, R. A.
2005; 20 (5): 988-990
 - **The kidney in preeclampsia** *KIDNEY INTERNATIONAL*
Lafayette, R.
2005; 67 (3): 1194-1203
 - **Examining chronic kidney disease management in a single center** *CLINICAL NEPHROLOGY*
Lafayette, R. A., Lai, G.
2004; 62 (4): 260-266
 - **The dynamics of glomerular filtration in the puerperium** *AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY*
Hladunewich, M. A., Lafayette, R. A., Derby, G. C., Blouch, K. L., Bialek, J. W., Druzin, M. L., Deen, W. M., Myers, B. D.
2004; 286 (3): F496-F503
 - **Nitric oxide pathway in pre-eclampsia.**
Hladunewich, M. A., Lafayette, R. A., Derby, G. C., Blouch, K. L., Bialek, J. W., Druzin, M. L., Myers, B. D.
LIPPINCOTT WILLIAMS & WILKINS.2003: 516A
 - **C-reactive protein, C-pneumoniae, H-pylgri, and vascular risk in end-stage renal disease.**
Lentine, K. L., Parsonnet, J., Lafayette, R. A.
LIPPINCOTT WILLIAMS & WILKINS.2003: 718A
 - **Glomerular filtration rate and its determinants in the early puerperium after normal pregnancy.**
Hladunewich, M. A., Derby, G. C., Blouch, K. L., Deen, W. M., Druzin, M., Myers, B. D., Lafayette, R. A.
LIPPINCOTT WILLIAMS & WILKINS.2002: 450A
 - **Improved management of patients with chronic kidney disease (CKD) towards recommended targets of care.**
Lai, G., Lafayette, R. A.
AMER SOC NEPHROLOGY.2002: 628A
 - **Does site of care influence achievement of targeted care in patients with chronic kidney disease (CKD)?**
Lai, G., Hladunewich, M., Lafayette, R. A.
AMER SOC NEPHROLOGY.2002: 702A
 - **Podocytopenia and disease severity in IgA nephropathy** *KIDNEY INTERNATIONAL*
Lemley, K. V., Lafayette, R. A., Safai, M., Derby, G., Blouch, K., Squarer, A., Myers, B. D.
2002; 61 (4): 1475-1485
 - **Increased alpha-1 adrenergic sensitivity in patients with renal failure**
Abiose, A. K., Lafayette, R., Moreno, H., Blaschke, T. F., Hoffman, B. B.
ELSEVIER SCIENCE INC.2001: 220A

- **Lack of prognostic value for cardiac troponin T and I and CKMB in patients with chronic renal failure on hemodialysis**
Schreiber, D. H., Petersen, J., Lafayette, R., Heidenreich, P. A.
LIPPINCOTT WILLIAMS & WILKINS.2000: 520
- **How does knocking out angiotensin II activity reduce renal injury in mice? Discussion** *AMERICAN JOURNAL OF KIDNEY DISEASES*
Lafayette, R. A.
2000; 35 (1): 166-169
- **The dynamics of glomerular filtration after caesarean section** *JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY*
Lafayette, R. A., Malik, T., Druzin, M., Derby, G., Myers, B. D.
1999; 10 (7): 1561-1565
- **Nature of glomerular dysfunction in pre-eclampsia** *KIDNEY INTERNATIONAL*
Lafayette, R. A., Druzin, M., Sibley, R., Derby, G., Malik, T., Huie, P., Polhemus, C., Deen, W. M., Myers, B. D.
1998; 54 (4): 1240-1249
- **Predictors of mortality and the provision of dialysis in patients with acute tubular necrosis** *27th Annual Meeting of the American-Society-of-Nephrology*
Chertow, G. M., Lazarus, J. M., Paganini, E. P., Allgren, R. L., Lafayette, R. A., Sayegh, M. H.
AMER SOC NEPHROLOGY.1998: 692-98
- **Renal artery stenosis in kidney transplants** *AMERICAN JOURNAL OF KIDNEY DISEASES*
Fervenza, F. C., Lafayette, R. A., Alfrey, E. J., Petersen, J.
1998; 31 (1): 142-148
- **Pretransplant renal dysfunction predicts poorer outcome in liver transplantation** *CLINICAL NEPHROLOGY*
Lafayette, R. A., Pare, G., Schmid, C. H., King, A. J., Rohrer, R. J., Nasraway, S. A.
1997; 48 (3): 159-164
- **Anaritide in acute tubular necrosis** *27th Annual Meeting of the American-Society-of-Nephrology*
Allgren, R. L., Marbury, T. C., Rahman, S. N., Weisberg, L. S., Fenves, A. Z., Lafayette, R. A., Sweet, R. M., Genter, F. C., Kurnik, B. R., Conger, J. D., Sayegh, M. H.
MASS MEDICAL SOC.1997: 828-34
- **Profound hypophosphatemia and isolated hyperphosphaturia in two cases of multiple myeloma** *AMERICAN JOURNAL OF KIDNEY DISEASES*
Dash, T., Parker, M. G., Lafayette, R. A.
1997; 29 (3): 445-448
- **Acute renal failure due to postinfectious glomerulonephritis during pregnancy** *AMERICAN JOURNAL OF KIDNEY DISEASES*
Fervenza, F., Green, A., Lafayette, R. A.
1997; 29 (2): 273-276
- **Utility and limitations of iothalamate as a filtration marker.**
Blouch, K., Lafayette, R., Myers, B. D.
WILLIAMS & WILKINS.1996: A0653
- **PREVENTING DISEASE PROGRESSION IN CHRONIC-RENAL-FAILURE** *AMERICAN FAMILY PHYSICIAN*
Lafayette, R. A.
1995; 52 (6): 1783-1791
- **RENAL ACID-BASE TRANSPORT - THE REGULATORY ROLE OF THE INNER MEDULLARY COLLECTING DUCT** *KIDNEY INTERNATIONAL*
Schwartz, J. H., Madias, N. E., Harrington, J. T., Perrone, R., Lafayette, R., Borkan, S.
1995; 47 (1): 333-341
- **MORBIDITY AND MORTALITY IN DIALYSIS PATIENTS** *KIDNEY INTERNATIONAL*
Port, F. K., Harrington, J. T., Lafayette, R., Brown, R. S., Levey, A. S., STEINMAN, T. L., Meyer, K., Madias, N. E., NEURINGER, J. R.
1994; 46 (6): 1728-1737
- **ACUTE-RENAL-FAILURE IN THE SETTING OF BONE-MARROW TRANSPLANTATION** *KIDNEY INTERNATIONAL*

Zager, R. A., Madias, N. E., Harrington, J. T., Singh, A., Perrone, R., King, A., Lafayette, R., Natov, S. N.
1994; 46 (5): 1443-1458

● **LIPIDS AND THE KIDNEY** *KIDNEY INTERNATIONAL*

Keane, W. F., Madias, N. E., Harrington, J. T., Pereira, B., Singh, A., Lafayette, R., Neuringer, J., Natov, S. N.
1994; 46 (3): 910-920

● **INCREASED SERUM CREATININE IN THE ABSENCE OF RENAL-FAILURE IN PROFOUND HYPOTHYROIDISM** *AMERICAN JOURNAL OF MEDICINE*

Lafayette, R. A., Costa, M. E., King, A. J.
1994; 96 (3): 298-299

● **RENIN PROFILING FOR DIAGNOSIS, RISK ASSESSMENT, AND TREATMENT OF HYPERTENSION** *KIDNEY INTERNATIONAL*

Laragh, J. H., Madias, N. E., Harrington, J. T., Strom, J., Singh, A. K., Lafayette, R., Levey, A. S., Cahan, D.
1993; 44 (5): 1163-1175

● **THE EFFECTS OF BLOOD-PRESSURE REDUCTION ON CYCLOSPORINE NEPHROTOXICITY IN THE RAT** *JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY*

Lafayette, R. A., Mayer, G., Meyer, T. W.
1993; 3 (12): 1892-1899

● **EFFECTS OF ANGIOTENSIN-II RECEPTOR BLOCKADE ON REMNANT GLOMERULAR PERMEABILITY** *KIDNEY INTERNATIONAL*

Mayer, G., Lafayette, R. A., Oliver, J., Deen, W. M., Myers, B. D., Meyer, T. W.
1993; 43 (2): 346-353

● **ANGIOTENSIN-II RECEPTOR BLOCKADE LIMITS GLOMERULAR INJURY IN RATS WITH REDUCED RENAL MASS** *JOURNAL OF CLINICAL INVESTIGATION*

Lafayette, R. A., Mayer, G., Park, S. K., Meyer, T. W.
1992; 90 (3): 766-771